Suppr超能文献

泛素羧基末端水解酶(UCH)家族去泛素化酶在肿瘤发生中的潜在作用以及针对它们开发的化学抑制剂。

Potential roles of UCH family deubiquitinases in tumorigenesis and chemical inhibitors developed against them.

作者信息

Xu Zhuo, Zhang Naixia, Shi Li

机构信息

State Key Laboratory of Chemical Biology, Analytical Research Center for Organic and Biological Molecules, Shanghai Institute of Materia Medica, Chinese Academy of Sciences 555 Zu Chong Zhi Road, Shanghai 201203, China.

University of The Chinese Academy of Sciences 19A Yuquan Road, Beijing 100049, China.

出版信息

Am J Cancer Res. 2024 Jun 15;14(6):2666-2694. doi: 10.62347/OEGE2648. eCollection 2024.

Abstract

Deubiquitinating enzymes (DUBs) are a large group of proteases that reverse ubiquitination process and maintain protein homeostasis. The DUBs have been classified into seven subfamilies according to their primary sequence and structural similarity. As a small subfamily of DUBs, the ubiquitin C-terminal hydrolases (UCHs) subfamily only contains four members including UCHL1, UCHL3, UCHL5, and BRCA1-associated protein-1 (BAP1). Despite sharing the deubiquitinase activity with a similar catalysis mechanism, the UCHs exhibit distinctive biological functions which are mainly determined by their specific subcellular localization and partner substrates. Besides, growing evidence indicates that the UCH enzymes are involved in human malignancies. In this review, the structural information and biological functions of the UCHs are briefly described. Meanwhile, the roles of these enzymes in tumorigenesis and the discovered inhibitors against them are also summarized to give an insight into the cancer therapy with the potential alternative strategy.

摘要

去泛素化酶(DUBs)是一类庞大的蛋白酶,可逆转泛素化过程并维持蛋白质稳态。根据其一级序列和结构相似性,DUBs已被分为七个亚家族。作为DUBs的一个小亚家族,泛素C末端水解酶(UCHs)亚家族仅包含四个成员,即UCHL1、UCHL3、UCHL5和BRCA1相关蛋白1(BAP1)。尽管UCHs具有相似的催化机制并共享去泛素酶活性,但它们表现出独特的生物学功能,这主要由其特定的亚细胞定位和伴侣底物决定。此外,越来越多的证据表明UCH酶与人类恶性肿瘤有关。在这篇综述中,简要描述了UCHs的结构信息和生物学功能。同时,还总结了这些酶在肿瘤发生中的作用以及已发现的针对它们的抑制剂,以期深入了解具有潜在替代策略的癌症治疗方法。

相似文献

1
Potential roles of UCH family deubiquitinases in tumorigenesis and chemical inhibitors developed against them.
Am J Cancer Res. 2024 Jun 15;14(6):2666-2694. doi: 10.62347/OEGE2648. eCollection 2024.
2
Ubiquitin carboxyl-terminal hydrolases: involvement in cancer progression and clinical implications.
Cancer Metastasis Rev. 2017 Dec;36(4):669-682. doi: 10.1007/s10555-017-9702-0.
3
4
The potential role of ubiquitin c-terminal hydrolases in oncogenesis.
Biochim Biophys Acta. 2010 Aug;1806(1):1-6. doi: 10.1016/j.bbcan.2010.03.001. Epub 2010 Mar 17.
5
Friend or Foe: UCHL3 Mediated Carcinogenesis and Current Approaches in Small Molecule Inhibitors' Development.
Curr Med Chem. 2021;28(42):8782-8799. doi: 10.2174/0929867328666210708085544.
6
7
Ubiquitin recognition of BAP1: understanding its enzymatic function.
Biosci Rep. 2017 Oct 27;37(5). doi: 10.1042/BSR20171099. Print 2017 Oct 31.
8
Development of Ubiquitin Variants with Selectivity for Ubiquitin C-Terminal Hydrolase Deubiquitinases.
Biochemistry. 2020 Sep 22;59(37):3447-3462. doi: 10.1021/acs.biochem.9b01076. Epub 2020 Sep 8.

引用本文的文献

1
UCHL3: a crucial deubiquitinase in DNA damage repair and tumor progression.
Cancer Cell Int. 2025 Jul 21;25(1):276. doi: 10.1186/s12935-025-03884-x.
4
Deubiquitinases as novel therapeutic targets for diseases.
MedComm (2020). 2024 Dec 13;5(12):e70036. doi: 10.1002/mco2.70036. eCollection 2024 Dec.
5
Ubiquitin-Proteasome System in Periodontitis: Mechanisms and Clinical Implications.
Cell Prolif. 2025 Mar;58(3):e13781. doi: 10.1111/cpr.13781. Epub 2024 Dec 3.

本文引用的文献

1
UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.
Cell Rep Med. 2024 Feb 20;5(2):101381. doi: 10.1016/j.xcrm.2023.101381. Epub 2024 Jan 19.
2
Nuclear AhR and membranous PD-L1 in predicting response of non-small cell lung cancer to PD-1 blockade.
Signal Transduct Target Ther. 2023 May 29;8(1):191. doi: 10.1038/s41392-023-01416-5.
3
Basis of the H2AK119 specificity of the Polycomb repressive deubiquitinase.
Nature. 2023 Apr;616(7955):176-182. doi: 10.1038/s41586-023-05841-y. Epub 2023 Mar 29.
4
Targeting BAP1 with small compound inhibitor for colon cancer treatment.
Sci Rep. 2023 Feb 8;13(1):2264. doi: 10.1038/s41598-023-29017-w.
5
Control of protein stability by post-translational modifications.
Nat Commun. 2023 Jan 13;14(1):201. doi: 10.1038/s41467-023-35795-8.
7
Deubiquitinase UCHL5 stabilizes ELK3 to potentiate cancer stemness and tumor progression in pancreatic adenocarcinoma (PAAD).
Exp Cell Res. 2022 Dec 15;421(2):113402. doi: 10.1016/j.yexcr.2022.113402. Epub 2022 Nov 1.
8
Structural basis for specific inhibition of the deubiquitinase UCHL1.
Nat Commun. 2022 Oct 10;13(1):5950. doi: 10.1038/s41467-022-33559-4.
9
Treatment with b-AP15 to Inhibit UCHL5 and USP14 Deubiquitinating Activity and Enhance p27 and Cyclin E1 for Tumors with Deficiency.
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221119745. doi: 10.1177/15330338221119745.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验